SEC Filing Summary: AVROBIO, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AVROBIO, Inc. (not Tectonic Therapeutic, Inc.) on November 19, 2020. The filing reports the entry into a material definitive agreement regarding an underwritten public offering of common stock. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Offering Size: 5,000,000 shares of Common Stock.
- Offering Price: $15.00 per share.
- Expected Gross Proceeds: Approximately $75 million (excluding underwriting discounts, commissions, and expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 750,000 shares.
- Underwriters: Morgan Stanley & Co. LLC and Cowen and Company, LLC.
- Expected Closing Date: On or about November 24, 2020.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses solely on the capital raise transaction.
Material Changes
The primary material change is the execution of an underwriting agreement to raise capital. This represents a significant increase in the company's equity capital base pending the closing of the transaction. No other material changes to operations or financial status are detailed in this specific report.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the completion, timing, and size of the offering, as well as the anticipated use of proceeds. Management explicitly disclaims any obligation to update these statements except as required by law.
Risks and Contingencies:
- Completion of the offering is subject to customary closing conditions.
- Market conditions could affect the ability to close the offering on anticipated terms.
- Investors are referred to the "Risk Factors" section of the company's 2019 Form 10-K and subsequent 10-Q filings for a comprehensive discussion of uncertainties.
Key Facts for Investor Verification
- Verify the final closing date and whether the over-allotment option was exercised.
- Confirm the net proceeds after deducting underwriting discounts and offering expenses.
- Review the Prospectus Supplement (dated November 19, 2020) for the specific intended use of proceeds.
- Check subsequent filings for any updates on the company's cash position and burn rate following the capital raise.